Drug Shortage Report for HEPARIN SODIUM INJECTION, USP

Last updated on 2023-02-09 History
Report ID 170980
Drug Identification Number 02264315
Brand name HEPARIN SODIUM INJECTION, USP
Common or Proper name HEPARIN SODIUM INJECTION, USP
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) HEPARIN SODIUM
Strength(s) 1000UNIT
Dosage form(s) SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS
Packaging size 30 mL
ATC code B01AB
ATC description ANTITHROMBOTIC AGENTS
Reason for shortage Other (Please describe in comments)
Anticipated start date 2022-10-03
Actual start date 2022-10-03
Estimated end date 2023-02-08
Actual end date 2023-02-08
Shortage status Resolved
Updated date 2023-02-09
Company comments Product is on 100% allocation
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v9 2023-02-09 French Compare
v8 2023-02-09 English Compare
v7 2023-02-09 French Compare
v6 2023-02-09 English Compare
v5 2023-01-02 French Compare
v4 2023-01-02 English Compare
v3 2022-10-04 English Compare
v2 2022-10-03 French Compare
v1 2022-10-03 English Compare

Showing 1 to 9 of 9